| 000 | 01816 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513213442.0 | ||
| 264 | 0 | _c20000816 | |
| 008 | 200008s 0 0 eng d | ||
| 022 | _a0014-4886 | ||
| 024 | 7 |
_a10.1006/exnr.2000.7410 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSautter, J | |
| 245 | 0 | 0 |
_aSystemic treatment with GM1 ganglioside improves survival and function of cryopreserved embryonic midbrain grafted to the 6-hydroxydopamine-lesioned rat striatum. _h[electronic resource] |
| 260 |
_bExperimental neurology _cJul 2000 |
||
| 300 |
_a121-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBrain Tissue Transplantation |
| 650 | 0 | 4 |
_aCell Count _xdrug effects |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aCorpus Striatum _xcytology |
| 650 | 0 | 4 |
_aCryopreservation _xmethods |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFetal Tissue Transplantation |
| 650 | 0 | 4 |
_aG(M1) Ganglioside _xpharmacology |
| 650 | 0 | 4 |
_aGraft Survival _xdrug effects |
| 650 | 0 | 4 |
_aMesencephalon _xcytology |
| 650 | 0 | 4 |
_aMotor Activity _xdrug effects |
| 650 | 0 | 4 |
_aNeurons _xcytology |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xpharmacology |
| 650 | 0 | 4 | _aOxidopamine |
| 650 | 0 | 4 |
_aParkinson Disease, Secondary _xchemically induced |
| 650 | 0 | 4 |
_aPregnatrienes _xpharmacology |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aRecovery of Function _xdrug effects |
| 650 | 0 | 4 |
_aTyrosine 3-Monooxygenase _xmetabolism |
| 700 | 1 | _aHöglinger, G U | |
| 700 | 1 | _aOertel, W H | |
| 700 | 1 | _aEarl, C D | |
| 773 | 0 |
_tExperimental neurology _gvol. 164 _gno. 1 _gp. 121-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1006/exnr.2000.7410 _zAvailable from publisher's website |
| 999 |
_c10828583 _d10828583 |
||